287 related articles for article (PubMed ID: 31091466)
21. Metformin and Angiogenesis in Cancer - Revisited.
Kannarkatt J; Alkharabsheh O; Tokala H; Dimitrov NV
Oncology; 2016; 91(4):179-184. PubMed ID: 27487294
[TBL] [Abstract][Full Text] [Related]
22. Tumor microenvironment components: Allies of cancer progression.
Ribeiro Franco PI; Rodrigues AP; de Menezes LB; Pacheco Miguel M
Pathol Res Pract; 2020 Jan; 216(1):152729. PubMed ID: 31735322
[TBL] [Abstract][Full Text] [Related]
23. Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk.
Hart PC; Kenny HA; Grassl N; Watters KM; Litchfield LM; Coscia F; Blaženović I; Ploetzky L; Fiehn O; Mann M; Lengyel E; Romero IL
Cell Rep; 2019 Dec; 29(12):4086-4098.e6. PubMed ID: 31851935
[TBL] [Abstract][Full Text] [Related]
24. Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis.
Griss T; Vincent EE; Egnatchik R; Chen J; Ma EH; Faubert B; Viollet B; DeBerardinis RJ; Jones RG
PLoS Biol; 2015 Dec; 13(12):e1002309. PubMed ID: 26625127
[TBL] [Abstract][Full Text] [Related]
25. Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer.
Samuel SM; Varghese E; Kubatka P; Triggle CR; Büsselberg D
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31835318
[TBL] [Abstract][Full Text] [Related]
26. Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?
Chandel NS; Avizonis D; Reczek CR; Weinberg SE; Menz S; Neuhaus R; Christian S; Haegebarth A; Algire C; Pollak M
Cell Metab; 2016 Apr; 23(4):569-70. PubMed ID: 27076070
[No Abstract] [Full Text] [Related]
27. Metformin: a metabolic modulator.
Pietrocola F; Kroemer G
Oncotarget; 2017 Feb; 8(6):9017-9020. PubMed ID: 28122334
[TBL] [Abstract][Full Text] [Related]
28. The prednisolone phosphate‑induced suppression of the angiogenic function of tumor‑associated macrophages enhances the antitumor effects of doxorubicin on B16.F10 murine melanoma cells in vitro.
Licarete E; Rauca VF; Luput L; Patras L; Sesarman A; Banciu M
Oncol Rep; 2019 Dec; 42(6):2694-2705. PubMed ID: 31578578
[TBL] [Abstract][Full Text] [Related]
29. Metformin and cancer: Quo vadis et cui bono?
Menendez JA; Martin-Castillo B; Joven J
Oncotarget; 2016 Aug; 7(34):54096-54101. PubMed ID: 27356748
[TBL] [Abstract][Full Text] [Related]
30. Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells.
Saini N; Yang X
Acta Biochim Biophys Sin (Shanghai); 2018 Feb; 50(2):133-143. PubMed ID: 29342230
[TBL] [Abstract][Full Text] [Related]
31. Metformin as an Anticancer Agent.
Vancura A; Bu P; Bhagwat M; Zeng J; Vancurova I
Trends Pharmacol Sci; 2018 Oct; 39(10):867-878. PubMed ID: 30150001
[TBL] [Abstract][Full Text] [Related]
32. Targeting tumor-associated macrophages to combat pancreatic cancer.
Cui R; Yue W; Lattime EC; Stein MN; Xu Q; Tan XL
Oncotarget; 2016 Aug; 7(31):50735-50754. PubMed ID: 27191744
[TBL] [Abstract][Full Text] [Related]
33. Glucocorticoid-mediated effects on angiogenesis in solid tumors.
Martens B; Drebert Z
J Steroid Biochem Mol Biol; 2019 Apr; 188():147-155. PubMed ID: 30654109
[TBL] [Abstract][Full Text] [Related]
34. Metformin effects on malignant cells and healthy PBMC; the influence of metformin on the phenotype of breast cancer cells.
Damjanović A; Matić IZ; Ðorđić M; Ðurović MN; Nikolić S; Roki K; Milovanović Z; Antić-Stanković J; Džodić R; Damjanović S; Kanjer K; Abu Rabi Z; Juranić Z
Pathol Oncol Res; 2015 Jul; 21(3):605-12. PubMed ID: 25351941
[TBL] [Abstract][Full Text] [Related]
35. Biology and therapeutic targeting of tumour-associated macrophages.
Beltraminelli T; De Palma M
J Pathol; 2020 Apr; 250(5):573-592. PubMed ID: 32086811
[TBL] [Abstract][Full Text] [Related]
36. Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies.
Darvishi B; Majidzadeh-A K; Ghadirian R; Mosayebzadeh M; Farahmand L
Life Sci; 2019 Jan; 217():34-40. PubMed ID: 30472294
[TBL] [Abstract][Full Text] [Related]
37. Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Christodoulou MI; Scorilas A
Curr Med Chem; 2017; 24(1):14-56. PubMed ID: 27604091
[TBL] [Abstract][Full Text] [Related]
38. Metformin is synthetically lethal with glucose withdrawal in cancer cells.
Menendez JA; Oliveras-Ferraros C; Cufí S; Corominas-Faja B; Joven J; Martin-Castillo B; Vazquez-Martin A
Cell Cycle; 2012 Aug; 11(15):2782-92. PubMed ID: 22809961
[TBL] [Abstract][Full Text] [Related]
39. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory angiogenesis and the tumor microenvironment as targets for cancer therapy and prevention.
Bruno A; Pagani A; Magnani E; Rossi T; Noonan DM; Cantelmo AR; Albini A
Cancer Treat Res; 2014; 159():401-26. PubMed ID: 24114493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
